GRIN-related neurodevelopmental disorder (GRIN-NDD) is a family of rare, genetically defined neurodevelopmental disorders caused by mutations in GRIN genes and abnormal activity of the ...
Our round-up of recent biotech financings is headed by a $140 million Series D for GRIN Therapeutics, which also scored a $570 million licensing deal with Angelini Pharma. The New York-based biotech ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results